ArticleActa neurologica Scandinavica2021
Refractory migraine profile in CGRP-monoclonal antibodies scenario.
Article in Acta neurologica Scandinavica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05442008 (Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine: a Real-life, Open-label, Trial
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.The journal of headache and pain · 2022Trial
- Review
- Observational
- Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry.The journal of headache and pain · 2026Article
- Clinical predictors for efficacy of erenumab for migraine: a Registry for Migraine (REFORM) study.Brain communications · 2025Article
- Psychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years.International journal of clinical pharmacy · 2024Article
- Application of Artificial Intelligence in the Headache Field.Current pain and headache reports · 2024Review
- Migraine Comorbidities.Life (Basel, Switzerland) · 2024Review
- Predictors of galcanezumab response in a real-world study of Korean patients with migraine.Scientific reports · 2023Article
- Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review.The journal of headache and pain · 2023Review
- Migraine Treatment: Towards New Pharmacological Targets.International journal of molecular sciences · 2023Review
- Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Observational
- A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.The journal of headache and pain · 2023Article
- Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.Brain and behavior · 2023Article
- Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study.The journal of headache and pain · 2023Observational
- Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine.Frontiers in neurology · 2023Review
- Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.Current pain and headache reports · 2022Review
- Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.The journal of headache and pain · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRefractory migraine (Ref-M) represents a conundrum that headache experts have to face with. We aim to investigate whether a peculiar profile may characterize patients with Ref-M according to 2020 European Headache Federation criteria. Furthermore, to substantiate a dysfunctional dopaminergic pathway involvement in these patients, we explored the effectiveness of olanzapine. MATERIALS &
methodsEighty-four patients (fitting previous Ref-M criteria of the 2014) were treated with erenumab for six months. Differences between clinical and demographic features of responder (Ref-M according to 2014 criteria) and not-responder (Ref-M according to 2020 criteria) patients to CGRP-mAbs were investigated and their predictive values assessed. In fifteen patients with Ref-M not responders to CGRP-mAbs, olanzapine was administered (5 mg/die) for 3 months and frequency and pain intensity of migraine attacks were estimated.
resultsPatients with Ref-M not responsive to CGRP-mAbs (29/84) when compared with Ref-M responsive to CGRP-mAbs showed higher baseline frequency of migraine attacks, medication overuse and pain catastrophizing scale (PCS) scores. Logistic regression analyses showed that frequency of attacks, medication overuse and PCS score represent independent negative predictors of CGRP-mAbs response. A ≥50% reduction of headache days/month was observed after olanzapine treatment in 67% of patients with Ref-M not responsive to CGRP-mAbs.
conclusionsWe outline that higher frequency of migraine attacks, medication overuse and pain catastrophizing characterize patients with Ref-M not responsive to CGRP-mAbs. In this frame, olanzapine effectiveness on frequency and pain intensity of migraine attacks supports the hypothesis that migraine refractoriness may be subtended by a prominent involvement of the dopaminergic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.